Details

Autor(en) / Beteiligte

• Ji, Biying
• Zhou, Fei
• Han, Lijuan
• Yang, Jun
• Fan, Haijian
• Li, Shanshan
• Li, Jingwei
• Zhang, Xin
• Wang, Xiaoying
• Chen, Xiangyan
• Xu, Yun

Titel

Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage

Ist Teil von

• Translational stroke research, 2017-08, Vol.8 (4), p.334-340

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Treatment with sodium tanshinone IIA sulfonate (STS) may ameliorate blood-brain barrier (BBB) damage in acute ischemic stroke patients receiving recombinant tissue plasminogen activator (rt-PA) thrombolysis and improve stroke patients’ outcome. This randomized, single-center, placebo-controlled clinical trial investigated the potential effects and underlying mechanisms of STS. Forty-two acute ischemic stroke patients receiving intravenous rt-PA thrombolysis were randomized to intravenous administration either with STS (60 mg/day) ( n  = 21) or with equivalent volume of saline as a placebo ( n  = 21) after randomization for 10 days. Clinical outcomes, computer tomography perfusion (CTP) imaging with permeability-surface area product (PS) maps and serum levels of BBB damage biomarkers, were compared between the two groups. The percentage of patients with excellent functional outcome indicated by a 90-day mRS ≤1 was significantly higher in the STS group than in the placebo group ( p  = 0.028). For patients with CTP imaging ( n  = 30), PS in the ipsilateral lesion ( p  = 0.034) and relative PS ( p  = 0.013) were significantly lower in the STS group than that in placebo. STS-treated patients also had lower levels of matrix metalloproteinase (MMP)-9 ( p  = 0.036) and claudin-5 ( p  = 0.026), but higher levels of tissue inhibitor of metalloproteinase (TIMP)-1 ( p  = 0.040) than those in the placebo group. Post-stroke STS treatment could improve neurologic functional outcomes for acute ischemic stroke patients following rt-PA treatment by reducing BBB leakage and damage, which might be mechanistically associated with MMP-9 inhibition.